Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter D. Mahalingam
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors D. Mahalingam1, M. Patel2, J. Sachdev3, L. Hart4, N. Halama5, R. Ramanathan6, J. Sarantopoulos7, X. Liu8, S. Yazji8, D. Jäger9, D. Adib8, R. Kerschbaumer10, M. Yoon8, G. Manzur8, A. Starodub11, K. Sivarajan12, M. Wertheim13, P. Thambi14, M. Jones15, S. Goel16, J. Nemunaitis17, A. Tsimberidou18
  • 1Univ. of Texas Health Sciences Center San Antonio, San Antonio, Texas, USA, /
  • 2Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida, /
  • 3Scottsdale Healthcare, Scottsdale, Arizona, USA, /
  • 4Florida Cancer Specialists, Fort Myers, Florida, USA, /
  • 5National Center for Tumor Diseases, University Medical Center Heidelberg, Heidelberg, Germany, /
  • 6Mayo Clinic, Scottsdale, Arizona, /
  • 7Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA, /
  • 8Baxalta, Cambridge, Massachusetts, USA, /
  • 9National Center for Tumor Diseases, Heidelberg, Germany, /
  • 10Baxalta Innovations GmbH, Vienna, Austria, /
  • 11Indiana University Health Center for Cancer Care, Goshen, Indiana, USA, /
  • 12Joliet Oncology-Hematology Associates, LTD, Joliet, Illinois, USA, /
  • 13Hematology - Oncology Associates of Treasure Coast, Port St Lucie, Florida, USA, /
  • 14Maryland Oncology Hematology, P.A., Rockville, Maryland, USA, /
  • 15The Jones Clinic, Germantown, Tennessee, USA, /
  • 16Albert Einstein College of Medicine, Montefiore Medical Center, New York, New York, USA, /
  • 17Mary Crowley Medical Research Center, Dallas, Texas, USA, /
  • 18University of Texas MD Anderson Cancer Center, Houston, Texas, USA, /

Abstract

MIF is a pleiotropic cytokine involved in tumor proliferation, invasiveness, angiogenesis, and proinflammation of the microenvironment. oxMIF is the pathogenic form mainly found in tumor and its surrounding stroma. Imalumab (Bax69) is a novel recombinant, fully human, monoclonal antibody targeting oxMIF. Preclinical data demonstrated imalumab has antitumor activity and acceptable toxicity. Here we present the results of the Phase I study in patients with advanced solid tumors (mCRC subset), which completed accrual and the preliminary results of the ongoing phase IIa study of imalumab in patients with mCRC (data cut-off, 19 Feb 2016).